New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 27, 2014
13:25 EDTACRXFDA issues Complete Response Letter for AcelRx NDA for Zalviso
AcelRx Pharmaceuticals announced that the U.S. Food and Drug Administration, FDA, has issued a Complete Response Letter, CRL, for the company's new drug application, NDA, for Zalviso, sufentanil sublingual tablet system. The company is currently reviewing the FDA's comments and requests contained in the CRL and plans to discuss these requests with the FDA.The CRL contains requests for additional information on the Zalviso System to ensure proper use of the device. The requests include provision of bench data demonstrating a reduction in the incidence of optical system errors which require premature drug cartridge change, changes to the Instructions for Use for the device, and additional data to support the shelf life of the product. We believe some of the requests have been addressed in amendments to the NDA that have been submitted prior to the receipt of the CRL but, as acknowledged by the FDA, have not been reviewed. There is no guarantee that the information previously provided to the FDA will be adequate to address the issues in the CRL. Additional bench testing will be required and human factors testing may be required to address certain items in the CRL. There were no requests to conduct additional human clinical studies. "We believe we can satisfy all of FDA's requests in the CRL and resubmit the NDA by the end of 2014, although we will have more clarity on the process and timing after our conversation with FDA," said Richard King, president and CEO of AcelRx. "We are confident in the Zalviso development program and will work closely with the FDA to address the Agency's concerns as outlined in the CRL to ensure that healthcare professionals and patient communities will have access to Zalviso."
News For ACRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 22, 2014
07:19 EDTACRXAcelRx's Zalviso for abdominal pain shows positive Phase 3 results
Subscribe for More Information
October 16, 2014
07:02 EDTACRXAcelRx updates patent portfolio for Zalviso and platform technologies
Subscribe for More Information
October 9, 2014
10:27 EDTACRXAcelRx management to meet with Guggenheim
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use